A drug originally used to boost the immune system is showing promise as a potential new treatment for lupus, joint Monash University and Peking University research published today shows. Lupus is an autoimmune disease, where the immune system attacks the body’s own organs and tissues.
An international team of scientists from Australia and China have, for the first time, shown in a study published in Nature Medicine, that a natural immune system protein called IL-2 can help restore balance to the overactive immune system of lupus patients. The drug could soon be rolled out for clinical trials in lupus treatment.
Monash Biomedicine Discovery Institute researcher, Dr Di Yu and Professor Zhanguo Li from Peking University People’s Hospital in China co-led the study.
Dr Yu said he hoped the drug could be approved as a lupus treatment within a handful of years.
“This drug, which can help the immune system fight against cancer, was approved in the 1990s but is not commonly used now. We’re now using this drug for a different purpose, based on our new knowledge of the immune system,” Dr Yu said.
“The amount we tested for treating lupus is much less than the dose used in treating cancers. We observed the treatment was safe and showed promising results, so there’s reason to believe formal trials could begin almost immediately,” he said.
Dr Yu said lupus could be a serious disease, and that it hadn’t been able to be treated in a very satisfactory way in the past.
IL-2 is a protein that regulates the activity of white blood cells, which are an important part of the immune system that protect the body against infections. In cancer therapy, patients are given large doses of IL-2 to stimulate their immune system but, paradoxically, the low dose IL-2 given to lupus sufferers in this study actually supressed the overactive part of their immune system that attacks their body. The research also showed the “self-checking” part of the immune system that prevents an overactive immune response, called regulatory T cells, increased after IL-2 treatment.
Professor Eric Morand, fellow Monash University researcher on the study and founder of the Asia Pacific Lupus Collaboration, said that in this study, IL-2 was given to people whose lupus wasn’t responding well to standard treatments.
“The real promise of this treatment is that it calms the hyperactive immune system through multiple mechanisms, which is very important as this new therapy may be effective for many patients,” Professor Morand said.
”As the drug has been on the market for some time for other diseases, it can be rapidly put into formal trials for lupus treatment right away.”
Learn more: Promising new treatment for lupus on the horizon
The Latest on: Lupus
via Google News
The Latest on: Lupus
Immunosuppressant Protective in Lupus Nephritis
on June 13, 2019 at 1:01 pm
MADRID -- A drug commonly used to prevent rejection of human transplanted organs, cyclosporine, may be useful in helping patients with lupus nephritis achieve remission from the serious kidney ... […]
Stelara Study Shows Promise for Lupus Treatment
on June 13, 2019 at 9:53 am
The annual congress of the European League Against Rheumatism (EULAR), which represents people with arthritis/rheumatism, health professionals and scientific societies of rheumatology of all the ... […]
Lupus walk returns Saturday to raise awareness of disease
on June 13, 2019 at 5:57 am
STOCKTON — Team Frankie has reassembled this year to continue to raise awareness about lupus. L for Lupus Foundation Presents: #TeamFrankie’s Third Annual Lupus Awareness Color Walk is from 10 a.m.-2 ... […]
Systemic Lupus Erythematosus Market Size to Exceed US$ 2.7 Bn by 2026
on June 13, 2019 at 2:32 am
Jun 13, 2019 (Global QYResearch via COMTEX) -- Global Systemic Lupus Erythematosus Market Size is anticipated to grow at 7.0 % CAGR during the forecast period and reach around US$ 2.7 Billion by 2026. ... […]
New biomarkers for cardiovascular risk in patients with juvenile-onset systemic lupus erythematosus (JSLE)
on June 13, 2019 at 12:31 am
The results of a study presented today at the Annual European Congress of Rheumatology (EULAR 2019) identify ApoB:A1 ratio and metabolomic lipoprotein signatures as potential biomarkers for ... […]
Heart Failure Risk High in Patients With Lupus
on June 12, 2019 at 9:34 am
Patients with systemic lupus erythematosus (SLE) are at increased risk for heart failure, with risks similar to those seen in patients with diabetes, an analysis of Medicaid data found. The incidence ... […]
Cars of Longmeadow raises money for Lupus research
on June 12, 2019 at 7:00 am
LONGMEADOW -- If you love cars, then mark your calendar for July 28 from 9 a.m. to noon. That’s when Cars of Longmeadow will hold its second annual car show. This year the event will be at The ... […]
Roche touts phase 2 Gazyva data in lupus patients with a potentially fatal kidney complication
on June 11, 2019 at 11:40 am
One brand-new FDA approval and one trial win for its blood cancer drug Gazyva added up to a double dose of good news for Roche Monday. The Swiss drugmaker snapped up a combo approval for lymphoma drug ... […]
10 Ways Lupus Has Made My Life Better
on June 11, 2019 at 10:38 am
After two years of learning to live with my diagnosis, I can finally see that some positive things have happened since I found out I have lupus. When I was first diagnosed, I spent most of my time and ... […]
Study Shows Gazyva® May Offer Potential New Treatment for Lupus Nephritis
on June 11, 2019 at 9:57 am
A new clinical trial investigating the safety and efficacy of Gazyva® (obinutuzumab) for adults with proliferative lupus nephritis (LN) announced encouraging initial results. The study showed that ... […]
via Bing News